

Thursday 26 August 2021

ACL FY21 FINANCIAL RESULTS

The following announcements to the market are attached:

- ✓ FY21 Appendix 4E

FY21 full year financial statements and statutory reports, including the FY21 directors' report

FY21 financial results investor presentation

– ENDS –

This announcement was authorised for release to ASX by the Board of ACL. For further information regarding this announcement, please contact:

Investors

Davina Gunn

Investor Relations

Email: investors@clinicallabs.com.au

Phone: +61 (0) 400 896 809

Company Secretary

Eleanor Padman

Company Secretary

Email: epadman@padmanadvisory.com.au

Phone: +61 (0) 422 002 918

About Australian Clinical Labs

ACL is a leading Australian private provider of pathology services. Our 86 NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.

Appendix 4E

Preliminary Financial Report

ASX Listing Rule 4.3A

Current reporting period:
Previous reporting period:

Financial year ended 30 June 2021
Financial year ended 30 June 2020

Results for announcement to the market		Percentage change %	30 June 2021 \$'m
<i>Statutory</i>			
Total revenue from ordinary activities	Up	31.8%	646.7m
Profit attributable to member of Australian Clinical Laboratories Limited	Up	46.3%	60.4m
<i>Pro forma</i>			
Total revenue from ordinary activities	Up	29.0%	674.4m
Profit attributable to member of Australian Clinical Laboratories Limited	Up	659.1%	88.7m

In line with the Prospectus dated 28 April 2021 pro forma financials reported above are on a normalised basis to adjust for initial public offer (IPO) transaction costs, SunDoctors acquisition and other significant one-off costs. These are discussed in full in the Financial Report attached.

Earnings per share		Percentage change %	30 June 2021 Cents per share
<i>Statutory</i>			
Basic and diluted earnings per share	Up	39.8%	39.69c
<i>Pro forma</i>			
Basic and diluted earnings per share	Up	625.3%	58.35c

Dividends		Amount per security Cents per share	Franked amount per security Cents per share
FY2021			
Final dividend (i)		Nil	Nil
Pre IPO dividend		14.25c	4.28c
FY2020			
Final dividend (ii)		14.45c	4.34c
Interim dividend		Nil	Nil
Record date for determining entitlements to the final dividend		Not applicable	

(i) The Board determined no final dividend would be paid in respect of the 2021 financial year which is in line with the recommendation within the Prospectus.

(ii) Dividend shown on a retrospective basis in line with the EPS calculations.

There are no dividend reinvestment plans in operation.

Appendix 4E

Preliminary Financial Report

Commentary on results for the period

For an explanation of the results refer to the ASX and media release and Financial Report.

Net tangible assets per ordinary security	30 June 2021	30 June 2020 ⁽ⁱ⁾
Net tangible assets per ordinary security	(\$0.15)	\$0.23
Net asset backing per ordinary security	\$0.41	\$0.47

- (i) Ordinary securities have been adjusted retrospectively for a restructure event that occurred prior to the IPO. Refer to Note 23 of the Financial Report for full details.

This report is based on the Financial Report which has been audited. Additional Appendix 4E disclosure requirements can be found in the Financial Report attached, which contains the Directors' Report, the audited Remuneration Report, the Directors' Declaration and the consolidated financial statements.